ERBB2 and breast carcinoma: Increased appreciation of the human epidermal growth factor receptor-2(HER2/neu) signalling pathway has led to the development of targetedtherapeutic agents used in conjunction with chemotherapy to improve outcomesfor HER2 overexpressing (HER2+) breast cancer.